Hereditary Genetic Testing Market Report 2025

This hereditary genetic testing market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The hereditary genetic testing market size has grown rapidly in recent years. It will grow from $21.47 billion in 2024 to $23.88 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to a rise in the incidence of inherited disease, growth in healthcare informatics, growth in telemedicine, growth in awareness campaigns, and a rising number of genetic testing platforms.

The hereditary genetic testing market size is expected to see rapid growth in the next few years. It will grow to $36.23 billion in 2029 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to the increasing prevalence of cancer, rising prevalence of genetic disorders, rising demand for diagnostics, increasing adoption of personalized medicine, and rising number of clinical trials. Major trends in the forecast period include technological advancements, whole-genome sequencing, integration of genetic data, personalized medicine, and non-invasive prenatal testing.

The rising prevalence of cancer is expected to drive the growth of the hereditary genetic testing market in the coming years. Cancer encompasses a group of diseases characterized by abnormal cell growth that can spread to other areas of the body. The increasing rate of cancer cases is linked to factors such as aging populations, lifestyle changes, exposure to environmental pollutants, genetic predispositions, and advancements in diagnostic methods. Hereditary genetic testing plays a key role in cancer prevention by identifying genetic mutations that increase cancer risk, facilitating early monitoring and targeted prevention efforts. For example, according to the Australian Institute of Health and Welfare, a government agency, the number of cancer cases diagnosed in Australia rose from 156,781 in 2021 to 160,570 in 2022, highlighting a year-over-year increase. Consequently, the growing prevalence of cancer is fueling the expansion of the hereditary genetic testing market.

Leading companies in the hereditary genetic testing industry are focusing on developing cutting-edge genomic solutions, such as multi-cancer multigene panels, to improve early detection and provide personalized treatment options. These multigene panels test for multiple genetic mutations across various cancers, supporting early diagnosis and customized treatment strategies. For instance, in February 2024, Exact Sciences Corporation, a U.S.-based provider of cancer screening and diagnostic tests, introduced the Riskguard hereditary cancer test. This test offers a personalized report on gene-specific and familial cancer risks using a simple blood or saliva sample for 10 common cancers. It helps patients understand their cancer risk, informs screening and treatment decisions, and assesses family-related cancer risks. Additionally, it aids in tailoring treatment for cancer patients and improving risk assessment for individuals with a family history of cancer by identifying actionable gene variants.

In January 2022, Exact Sciences Corp., a U.S.-based molecular diagnostics company, acquired PreventionGenetics for an undisclosed sum. This acquisition was intended to enhance Exact Sciences Corp.'s portfolio of advanced cancer diagnostics and support its entry into hereditary cancer testing. PreventionGenetics is a U.S.-based genetic testing laboratory.

Major companies operating in the hereditary genetic testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Amgen Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, Fulgent Genetics Inc., BioReference Laboratories Inc., BGI Group, Invitae Corporation, NeoGenomics Laboratories Inc., 23andMe Inc., MyHeritage Ltd., Color Health Inc., MedGenome Inc., SOPHiA GENETICS SA, Devyser AB, Mapmygenome India Ltd., Igenomix S.L.

North America was the largest region in the hereditary genetic testing market in 2024 and it is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary genetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hereditary genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hereditary genetic testing is a medical procedure that analyzes deoxyribonucleic acid (DNA) to detect inherited gene mutations that may lead to disease. It helps assess an individual's risk of developing certain genetic conditions passed down from parents to offspring. This type of testing is commonly used for conditions such as cancer, heart disease, and rare inherited disorders.

The primary types of hereditary genetic testing include predictive and presymptomatic testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and others. Predictive and presymptomatic testing identifies individuals at risk of developing specific diseases before symptoms manifest. The technologies used for testing include cytogenetic testing, biochemical testing, and molecular testing. Clinical applications encompass genetic testing for cancer, cardiovascular conditions, neurological disorders, and rare diseases. End users include hospitals and clinics, diagnostic laboratories, research institutes, and direct-to-consumer (DTC) genetic testing companies.

The hereditary genetic testing market research report is one of a series of new reports that provides hereditary genetic testing market statistics, including hereditary genetic testing industry global market size, regional shares, competitors with a hereditary genetic testing market share, detailed hereditary genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary genetic testing industry. This hereditary genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hereditary genetic testing market includes revenues earned by entities by providing services such as carrier screening, prenatal testing, and newborn screening. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.